AKAlaa Kandil

Alaa Kandil

*This is an algorithmically generated author record based on publicly available information.

Alaa Kandil has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline

    by Sana Al Sukhun, Sarah Temin, Carlos H. Barrios, Nicoleta Zenovia Antone, Yanin Chavarri Guerra, Mariana Chavez-MacGregor, Rakesh Chopra, Michael A. Danso, Henry Leonidas Gomez, N’dA Marcelin Homian, et al.

    PURPOSE: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting–guideline recommended treatment is unavailable. METHODS: A multidisciplinary, multinational panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes. RESULTS: Four published resource-agnostic guidelines were adapted for resource-constrained settings; informing two rounds of formal consensus; recommendations received ≥75% agreement. RECOMMENDATIONS: Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone. For life-threatening disease, use single-agent chemotherapy or surgery for local control. For premenopausal patients, use ovarian suppression or ablation plus hormone therapy in Basic settings. For human epidermal growth factor receptor 2 (HER2)–positive MBC, if trastuzumab, pertuzumab, and chemotherapy are unavailable, use trastuzumab and chemotherapy; if unavailable, use chemotherapy. For HER2-positive, HR-positive MBC, use standard first-line therapy, or endocrine therapy if contraindications. For triple-negative MBC with unknown PD-L1 status, or if PD-L1–positive and immunotherapy unavailable, use single-agent chemotherapy. For germline BRCA1/ 2 mutation–positive MBC, if poly(ADP-ribose) polymerase inhibitor is unavailable, use hormonal therapy (HR-positive MBC) and chemotherapy (HR-negative MBC). In second-line, for HR-positive MBC, Enhanced setting recommendations depend on prior treatment; for Limited, use tamoxifen or chemotherapy. For HER2-positive MBC, if trastuzumab deruxtecan is unavailable, use trastuzumab emtansine; if unavailable, capecitabine and lapatinib; if unavailable, trastuzumab and/or chemotherapy (hormonal therapy alone for HR-positive MBC). Additional information is available at www.asco.org/resource-stratified-guidelines . It is ASCO's view that healthcare providers and system decision-makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.


  • Open Access

    Serum Protein C and D-Dimer as Predictors of Portal Vein Thrombosis in Cirrhotic Patients without Hepatocellular Carcinoma

    by Alaa Kandil, Samir Kabil, Ahmed Mahmoud, Mohammed Fouda, Seham Gouda Ameen, Ahmed Fouda

    Background: Although the exact origin of portal vein thrombosis (PVT) is unknown, many studies have linked it to systemic factors like protein C, protein S as well as antithrombin III deficiencies. Other studies have linked it to the elevation of D-dimer and international normalized ratio (INR). Objective: To evaluation of serum protein C, D-dimer and INR as predictors of portal vein thrombosis among cirrhotic patients without hepatocellular carcinoma (HCC). Patients and methods: In a cross-sectional study a total 60 patient were included, 30 cirrhotic patients without PVT (Group I) and 30 cirrhotic patients with PVT (Group II), who were collected from patients who attended the outpatient and inpatient of The Department of Gastroenterology, Hepatology and Infectious Diseases, Faculty of Medicine, University of Benha. Levels of D dimer, protein C and INR were assessed among all participants. Results: This present study showed that D-dimer and INR levels in Group II were higher than Group I. In contrast it found that protein C is lower in Group II than in Group I. Positive correlation was found between alanine transaminase (ALT), aspartate transaminase (AST), serum creatinine, total bilirubin, INR and D-dimer levels with severity and deterioration of liver disease (Child score) especially with cirrhotic patients with PVT. Negative correlation was found between platelet count, serum albumin and protein C blood level with severity and deterioration of liver disease especially with cirrhotic patients with PVT. Conclusion: Decreased protein C, increased D-dimer and INR values were considered risk factors for formation of PVT among cases with liver cirrhosis, so it is important to conduct specific imaging techniques in order to validate the diagnosis and start treatment early.

  • Open Access

    Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

    by Khalid AlSaleh, Heba Al Zahwahry, Adda Bounedjar, Mohammed Oukkal, Ahmed Saadeddine, Hassen Mahfouf, Kamel Bouzid, Assia Bensalem, Taha Filali, Hikmat Abdel-Razeq, et al.

    PURPOSE: Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not completely understood which patients might benefit from neoadjuvant hormone therapy (NAHT). MATERIALS AND METHODS: The SAFIA trial is a prospective multicenter, international, double-blind, neoadjuvant phase III trial, using upfront 21-gene Oncotype DX Breast Recurrence Score assay (recurrence score [RS] < 31) to select operable luminal human epidermal growth factor receptor 2–negative patients, for induction hormonal therapy HT (fulvestrant 500 mg with or without goserelin) before randomly assigning responding patients to fulvestrant 500 mg (with or without goserelin) plus either palbociclib (cyclin-dependent kinase 4/6 inhibitor) or placebo. The objectives of this interim analysis were to assess the feasibility of upfront RS determination on core biopsies in the Middle-East and North Africa region and evaluate the efficacy of induction NAHT in patients with an RS < 31. RESULTS: At the time of this interim analysis, 258 patients with relative risk were accrued, including 202 patients (RS < 31% to 78.3%) treated with induction NAHT and 182 patients evaluable so far for response. The feasibility of performing the Oncotype DX assays on core biopsy specimens was optimal in 96.4% of cases. Overall, 93.4% of patients showed hormone sensitivity and no difference in NAHT efficacy was noticed between RS 0-10, 11-25, and 26-30. Interestingly, patients with high RS (26-30) showed a trend toward a higher major response rate ( P = .05). CONCLUSION: The upfront 21-gene assay performed on biopsies is feasible in our population and has allowed us to select patients with high hormone sensitivity (RS < 31). This approach could be an alternative to upfront surgery without significant risk of progression, particularly during pandemic times.


  • Open Access

    Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

    by Hesham Elghazaly, Hope S. Rugo, Hamdy A. Azim, Sandra M. Swain, Banu Arun, Matti Aapro, Edith A. Perez, Benjamin O. Anderson, Frederique Penault-Llorca, Pierfranco Conte, et al.

    Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.